Close Menu

NEW YORK (360Dx) – Startup True Bearing Diagnostics has cemented plans to launch an RNA-based test for coronary artery disease and is working on collecting the validation evidence it intends to submit to the US Food and Drug Administration for the assay early next year.

The company, founded in 2015, is the fruit of support provided by St. Laurent Institute to encourage what True Bearing CEO Tisha Jepson said has been a variety of projects applying SeqLL's amplification-free sequencing platform to the identification of novel disease signatures.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.